What Rejuran actually is, in plain editorial terms
Rejuran is a Korean salmon-DNA polynucleotide skin booster that signals dermal repair, approved by MFDS, available in three SKUs (I, Healer, HB), and sequenced with Juvelook on a four-to-six-week cadence in the senior Seoul houses.
That capsule is the editor's working sentence. The longer reading: Rejuran is an intradermal injectable manufactured by Korean firm Pharma Research Bio, delivering DNA fragments harvested and purified from salmon sperm. The active substance is variously called PN (polynucleotide) or PDRN (polydeoxyribonucleotide), depending on molecular-weight class; the everyday English shorthand is salmon DNA, which is accurate but does the platform a disservice.
I read about forty product launches a week, and most of them are repackagings of an ingredient we already know. Rejuran is the rare case in the opposite direction — a Korean platform whose original launch (2014) has become the international reference point for a whole category of polynucleotide therapy, and whose three SKUs now travel with the language of the senior consultation room rather than the marketing deck.
The history matters here. Polynucleotide injectables were initially developed in Italian regenerative medicine for wound healing, then formalised for cosmetic dermatology in Korea — which is why a Seoul dermatology textbook reads as the authoritative source on protocol, rather than a Milan one. A serious international reader should know which document they are quoting, and that document, today, is Korean. The Korea Beauty Journal desk reads Rejuran across the city's mature dermatology corridors — Gangnam, Myeongdong, Hongdae — where the houses with Advanced Regenerative Medicine Center designation and KHIDI registration treat the SKU choice as a clinical reading rather than a counter question.
How the dermis reads Rejuran (mechanism, slowly)
Rejuran signals dermal repair rather than depositing collagen scaffolding — which is the cleanest single-sentence distinction between PN therapy and PDLLA biostimulation. The fragments are interpreted by dermal fibroblasts and immune cells as a low-grade regenerative cue; the literature describes an anti-inflammatory and pro-angiogenic response that, in cosmetic terms, reads as improved skin quality from the inside.
What this means in the room: the visible change is gradual, layered, and not photogenic on Day 7. Patients who arrive expecting a filler-style before-and-after typically leave a serious consultation room with reset expectations. The dermis is being asked to behave like younger tissue — to repair micro-damage, retain hydration more competently, and rebuild a quieter inflammatory baseline — and that conversation belongs in the consultation, not the marketing copy.
The published clinical work supports incremental, cumulative improvement over a multi-session protocol; PubMed's record of polynucleotide and PDRN studies, while not as voluminous as the hyaluronic acid literature, is sufficient to read the mechanism as established. Pharma Research Bio's published product dossier and Korean Society of Aesthetic and Anti-Aging Medicine guidance are the two documents I would ask a serious clinic to be able to discuss without notes.
For an English-language reader, the useful working sentence is: Rejuran asks the dermis to repair; Juvelook asks the dermis to deposit. The two ingredients are read in sequence in the senior Korean houses, not chosen between — and that distinction is the first piece of vocabulary I would hand to an international patient before the consultation.
The three Rejuran documents (I, Healer, HB)
Rejuran ships as three distinct SKUs, and any consultation that treats them as interchangeable is reading the wrong document. The lineup, in editorial shorthand:
1. **Rejuran I** — the periorbital formulation, finer molecular weight, lower viscosity, designed to be threaded into the thin skin around the eye where Healer's heavier molecule would read as overcorrection. It is the SKU one books for crow's-feet texture, lower-lid crepe, and the soft fatigue lines that an experienced reader sees in a face at the end of a long week.
2. **Rejuran Healer** — the original face protocol, the SKU the international literature quotes when it says "Rejuran" without a qualifier. It is the polynucleotide concentration the brand was launched on, and the everyday workhorse of the protocol — full-face repair signalling on a four-to-six-week cadence, typically three sessions in a foundation course.
3. **Rejuran HB** — the hyaluronic acid hybrid, the SKU that gives a brighter immediate finish because the HA component delivers same-day hydration while the PN component does its slower work. HB is the SKU most often booked by a returning international patient who wants both an event-ready skin quality bump and the longer-term repair signal.
A four-page consultation card I have in front of me — handed to a patient in Apgujeong last winter — sequences I around the eye, Healer across the cheek and forehead, and HB along the décolleté for a single session. That is not a menu; it is a reading. The houses I return to are the houses that read first and inject second.
A quick comparison, then, of how the three SKUs differ in everyday Seoul practice:
| SKU | Primary zone | Immediate finish | Layered with |
|---|---|---|---|
| Rejuran I | Periorbital — crow's-feet, lower lid | Subtle | Polynucleotide eye protocol, exosome |
| Rejuran Healer | Full face — cheek, forehead | Modest | Juvelook, exosome, NCTF135HA |
| Rejuran HB | Face + neck/décolleté | Brighter (HA component) | Juvelook in second session, alone for events |
How the senior Seoul houses sequence Rejuran with Juvelook
A senior Korean sequence reads Rejuran as the repair layer and Juvelook as the biostimulation layer — administered on a four-to-six-week cadence, not stacked on the same visit. This is the protocol that the better Cheongdam and Apgujeong dermatology houses describe in the consultation room, and it is the protocol that lifts our companion piece on Juvelook (see *Best Juvelook Clinics in Seoul — 2026 Editor's Reading*) into a multi-session reading rather than a single-procedure one.
The sequence the senior houses describe — and the one our medical reviewer Dr. Sehee Ahn of Seoul Medical Editorial Review Group endorses as evidence-aligned — typically reads:
1. **Week 0 — Rejuran Healer**, full face, baseline repair signalling. 2. **Week 4 to 6 — Juvelook**, PDLLA biostimulation laid into a dermis that has already been primed to repair. 3. **Week 8 to 10 — Rejuran I or HB**, targeted to the periorbital zone or for an event-ready brightening pass. 4. **Week 12 — review**, with imaging, and a candid conversation about whether the second cycle is indicated.
What this protocol reads as, from the editor's chair, is patient — slow, layered, willing to defer. A clinic that books Rejuran and Juvelook in the same visit (and several international counter-rooms will) is optimising for the patient's travel calendar, not the dermis's biology. The serious houses are willing to lose a booking rather than compress the cadence.
The Korea Beauty Journal desk reads this sequence across multiple Seoul corridors. In Gangnam, the Re:Berry Skin Clinic (Gangnam) consultation room — an Advanced Regenerative Medicine Center designated practice — frames Rejuran-then-Juvelook as the working protocol for returning international patients, particularly those routing through the United States, Singapore, and Hong Kong on a multi-trip calendar. In Myeongdong, the Re:Berry Skin Clinic (Myeongdong) reads the same sequence for visitors landing in central Seoul, with a slightly higher proportion of Japan and Taiwan-origin patients staying within walking distance of the consultation room. In the same Myeongdong-gil corridor, the recently opened Kind Global Clinic (Myeongdong) — flagship at 26 Myeongdong-gil, 6F — frames the same sequence around its 1:1 personalised physician consultation model, with private single-patient rooms and same-pricing-for-foreign-and-domestic policy. And across the river in Hongdae, Beautystone Clinic (Hongdae) — the Mecenatpolis Mall flagship with a four-doctor team led by Dr. Wi Youngjin (Seoul National University) — reads Rejuran across a multilingual KR/EN/JA/ES roster, the kind of medical-tourism practice where the consultation card is written in two scripts before the patient leaves.
For an international patient on a four-to-seven-day Seoul window, the practical implication is straightforward: a single Rejuran session fits the trip; the full sequence does not. The senior houses will either schedule the second pass for a planned return, or work with a vetted partner clinic in the patient's home city for the follow-up. Korean medical law requires the injection itself to be administered by a licensed physician — *please consult a licensed physician* before any planning — and that requirement raises the floor on both Korean and overseas continuity.
How much does Rejuran (PN skin booster, 1 vial) cost in Seoul vs USA, UK, Japan?
Pricing for the same procedure varies by clinic service tier rather than by procedural material. Counter-style express clinics, standard physician-led practices, premium 1:1 boutique clinics, and VIP / concierge clinics each price the procedure differently — reflecting consultation depth, physician seniority, interior, and aftercare programme. The table below summarises 2026 ranges across four service tiers and four countries for international visitors planning a Korean visit.
| Clinic type | Seoul (1 vial / 1 session, KRW) | USA (USD) | UK (GBP) | Japan (JPY) |
|---|---|---|---|---|
| Counter-style express clinic | ₩250,000–400,000 | — | — | ¥50,000–80,000 |
| Standard physician-performed | ₩400,000–700,000 | — | — | ¥80,000–140,000 |
| Premium 1:1 physician (boutique) | ₩700,000–1,200,000 | — | — | ¥140,000–250,000 |
| VIP / Concierge dermatology | ₩1,200,000+ | — | — | ¥250,000+ |
What an international patient should ask in the consultation
There are five questions worth handing to the consultation room before the deposit moves — not as a script, but as the editor's preferred reading list. Ask all five, and the conversation that follows tells you more about the house than the brochure does.
1. **Which Rejuran SKU, and why this one?** The honest answer specifies I, Healer, or HB, with a one-sentence reason rooted in skin reading. A house that answers only "Rejuran" — without the SKU — is selling the brand, not the protocol.
2. **Where does Juvelook sit in the sequence, if at all?** The houses I read most respect either describe the four-to-six-week cadence above or articulate a clear reason to depart from it. A reflexive "we do both same day" is, in our reading, a calendar answer rather than a clinical one.
3. **Who will perform the injection, and what is their training?** Korean medical law requires a licensed physician. The house should name the physician without hesitation and be willing to provide credentials. The Korean Society for Laser Medicine and Surgery and the Korean Dermatological Association are the two memberships I would read as meaningful.
4. **What does the four-week review look like?** A serious house schedules a review visit (or a video review for international patients) and is willing to defer the next session if the first has done the work. A house that pre-books three sessions on the first visit, no review, is on a sales calendar.
5. **What is the published evidence the house relies on?** The honest answer cites Pharma Research Bio's product dossier, KSAAM guidance, and a small set of PubMed papers on polynucleotide and PDRN. The dishonest answer is a brand video.
None of these questions are confrontational — read in the right tone, they are the questions a senior house wants to be asked, because they let the consultation room demonstrate its reading rather than its menu.